跳至主要内容
临床试验/CTRI/2023/06/054367
CTRI/2023/06/054367尚未招募4 期

A comparative study of low dose Bupivacaine 0.5% (heavy), Levobupivacaine 0.5% (plain) and Levobupivacaine 0.5% (heavy) with Fentanyl as an adjuvant in Transurethral Resection of Prostate surgery: A prospective randomized study

Dr Sanyukta Paul1 个研究点 分布在 1 个国家目标入组 105 人开始时间: 2023年3月7日最近更新:

试验速览

阶段
4 期
状态
尚未招募
发起方
入组人数
105
试验地点
1
主要终点
Expected prolonged efficacy of Levobupivacaine 0.5% heavy over Bupivacaine 0.5% heavy & Levobupivacaine 0.5% plain

研究概览

简要总结

This is a prospective randomized study comparing low dose intrathecal Levobupicaine 0.5% heavy, Levobupivacaine 0.5% plain and Bupivacaine 0.5% heavy with Fentanyl as an adjuvant in Transurethral resection of prostate surgeries. In this study, we are comparing the onset and duration of motor block and sensory block, to study intraoperative hemodynamics and to study the untoward side effects,if any.

研究设计

研究类型
Interventional
分配方式
Other
盲法
Participant and Investigator Blinded

入排标准

年龄范围
50.00 Year(s) 至 75.00 Year(s)(—)
性别
Male

入选标准

  • Patient giving consent to participate in study Age between 50-75 years Weight between 45-70 kg ASA grade I and II Patient scheduled for TURP surgeries.

排除标准

  • Patients not giving consent to participate in the study.
  • Uncooperative patient ASA grade III and IV Patients with respiratory, cardiovascular, renal diseases, obesity.
  • Neurological disease (multiple sclerosis, symptomatic lumbar herniated disc, spinal stenosis) Coagulopathy Patient with known hypersensitivity to local anaesthetic.
  • Local sepsis or infection.

结局指标

主要结局

Expected prolonged efficacy of Levobupivacaine 0.5% heavy over Bupivacaine 0.5% heavy & Levobupivacaine 0.5% plain

时间窗: 24 hours

次要结局

  • Expected lesser side effects & stable hemodynamic profile with Levobupivacaine 0.5% heavy than Bupivacaine 0.5% heavy and Levobupivacaine 0.5% plain(24 hours)

研究者

发起方
Dr Sanyukta Paul
申办方类型
Other [self]

研究点 (1)

Loading locations...

相似试验